Monopar Therapeutics Inc

MNPR broke out above a prolonged base on strong momentum and elevated volume, confirming a medium-term bullish structure with rising EMAs and higher highs/lows. However, price is now extended above the 9/21 EMA cluster and showing extreme overbought readings. Execution is deferred—favor pullbacks into the rising EMA support zone or prior resistance-turned-support for optimal entry.

• ↑Phase 3 FoCus trial of ALXN1840 demonstrated p=0.006 neurologic gains in Wilson disease patients
• ↑Monopar holds $137.5 M cash and investments, supporting R&D through YE 2027
• ↓Negative earnings yield indicates valuation may not reflect profit potential